[1] R. D. Miller, “Miller’s Anesthesia,” 7th Edition, Churchill Livingstone, Orlando, 2009.
[2] A. E. Emery, “Population Frequencies of Inherited Neuromuscular Diseases—A World Survey,” Neuromuscular Disorders, Vol. 1, No. 1, 1991, pp. 19-29. doi:10.1016/0960-8966(91)90039-U
[3] D. Kedlaya, “Physical Medicine and Rehabilitation for Charcot-Marie-Tooth Disease,” 2012. http://emedicine.medscape.com/article/315260
[4] B. Bissonnette, I. Luginbuehl, B. Marciniak, B. Dalens, “Syndromes: Rapid Recognition and Perioperative Implications,” McGraw-Hill, New York, 2006, pp. 153-155.
[5] J. Burns, P. Bray, L. A. Cross, K. N. North, M. M. Ryan and R. A. Ouvrier, “Hand Involvement in Children with Charcot-Marie-Tooth Disease Type 1A,” Neuromuscular Disorders, Vol. 18, No. 12, 2008, pp. 970-973. doi:10.1016/j.nmd.2008.08.004
[6] E. M. Yiu, N. Geevasinga, G. A. Nicholson, E. R. Fagan, M. M. Ryan and R. A. Ouvrier, “A Retrospective Review of X-Linked Charcot-Marie-Tooth Disease in Childhood,” Neurology. Vol. 76, No. 5, 2011, pp. 461-466. doi:10.1212/WNL.0b013e31820a0ceb
[7] B. G. Kousseff, T. A. Hadro, D. L. Treiber, T. Wollner and C. Morris, “Charcot-Marie-Tooth Disease with Sensorineural Hearing Loss—An Autosomal Dominant Trait,” Birth Defects Original Article Series, Vol. 18, No. 3B, 1982, pp. 223-228.
[8] T. Stojkovic, P. Latour, A. Vandenberghe, J. F. Hurtevent and P. Vermersch, “Sensorineural Deafness in X-Linked Charcot-Marie-Tooth Disease with Connexin 32 Mutation (R142Q),” Neurology, Vol. 52, No. 4, 1999, pp. 1010 1014. doi:10.1212/WNL.52.5.1010
[9] T. Sevilla, et al., “Vocal Cord Paresis and Diaphragmatic Dysfunction Are Severe and Frequent Symptoms of GDAP1-Associated Neuropathy,” Brain, Vol. 131, No. 11, 2008, pp. 3051-3061. doi:10.1093/brain/awn228
[10] J. Burns, R. A. Ouvrier, E. M. Yiu and M. M. Ryan, “Extended Treatment of Childhood Charcot-Marie-Tooth Disease with High-Dose Ascorbic Acid,” Journal of the Peripheral Nervous System, Vol. 16, No. 3, 2011, pp. 272 274. doi:10.1111/j.1529-8027.2011.00348.x
[11] J. Bradbury, “Antiprogesterone Hope for Inherited Neuropathy,” The Lancet Neurology, Vol. 3, No. 1, 2004, p. 6. doi:10.1016/S1474-4422(03)00636-7
[12] J. F. Antognini, “Anaesthesia for Charcot-Marie-Tooth Disease: A Review of 86 Cases,” Canadian Journal of Anesthesia, Vol. 39, No. 4, 1992, pp. 398-400. doi:10.1007/BF03009054
[13] H. J. Schmitt, S. Wick and T. Münster, “Onset and Duration of Mivacurium-Induced Neuromuscular Blockade in Children with Charcot-Marie-Tooth Disease. A Case Series with Five Children,” Paediatric Anaesthesia, Vol. 16, No. 2, 2006, pp. 182-187. doi:10.1111/j.1460-9592.2005.01627.x
[14] A. S. Baraka, “Vecuronium Neuromuscular Block in a Patient with Charcot-Marie-Tooth Syndrome,” Anesthesia & Analgesia, Vol. 84, No. 4, 1997, pp. 927-928.
[15] D. Pogson, J. Telfer and S. Wimbush, “Prolonged Vecu ronium Neuromuscular Blockade Associated with Charcot Marie Tooth Neuropathy,” British Journal of Anaesthesia, Vol. 85, No. 6, 2000, pp. 914-917. doi:10.1093/bja/85.6.914
[16] M. Brock, C. Guinn and M. Jones, “Anesthetic Management of an Obstetric Patient with Charcot-Marie-Tooth Disease: A Case Study,” American Association of Nurse Anesthetists, Vol. 77, No. 5, 2009, pp. 335-337.
[17] S. Dhir, S. Balasubramanian and D. Ross, “Ultrasound Guided Peripheral Regional Blockade in Patients with Charcot-Marie-Tooth Disease: A Review of Three Cases,” Canadian Journal of Anesthesia, Vol. 55, No. 8, 2008, pp. 515-520. Vol. 77, No. 5, 2009, pp. 335-337.
[18] A. Bosenberg and K. Larkin, “Anaesthesia and Charcot Marie-Tooth Disease,” Southern African Journal of Anaesthesia & Analgesia, Vol. 12, No. 4, 2006, pp. 131-133.